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Abstract
The COVID-19 pandemic caused by SARS-CoV-2 infection has led to socioeconomic shutdowns and the loss of over 5 million lives worldwide. There is a
need for the identification of therapeutic targets to treat COVID-19. SARSCoV-2 spike is a target of interest for the development of therapeutic targets.
We developed a robust SARS-CoV-2 S spike expression and purification protocol from insect cells and studied four recombinant SARS-CoV-2 spike protein
constructs based on the original SARS-CoV-2 sequence using a baculovirus
expression system: a spike protein receptor-binding domain that includes the
SD1 domain (RBD) coupled to a fluorescent tag (S-RBD-eGFP), spike
ectodomain coupled to a fluorescent tag (S-Ecto-eGFP), spike ectodomain with
six proline mutations and a foldon domain (S-Ecto-HexaPro(+F)), and spike
ectodomain with six proline mutations without the foldon domain (S-EctoHexaPro(-F)). We tested the yield of purified protein expressed from the insect
cell lines Spodoptera frugiperda (Sf9) and Trichoplusia ni (Tni) and compared
it to previous research using mammalian cell lines to determine changes in
protein yield. We demonstrated quick and inexpensive production of functional glycosylated spike protein of high purity capable of recognizing and
binding to the angiotensin converting enzyme 2 (ACE2) receptor. To further
confirm functionality, we demonstrate binding of eGFP fused construct of the
spike ectodomain (S-Ecto-eGFP) to surface ACE2 receptors on lung epithelial
cells by flow cytometry analysis and show that it can be decreased by means of
receptor manipulation (blockade or downregulation).
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1 | INTRODUCTION
Although existing previously, coronaviruses have only
had their descriptive name (meaning “crown”) since
1962.1 With a total of 24 similar species in the wild, only
seven are known to cause disease in humans.2–6 Of these
seven, the most pathogenic members are severe acute
respiratory syndrome coronavirus (SARS-CoV, originating in Guangdong China in 2002), Middle East respiratory syndrome coronavirus (MERS-CoV, originating in
the Arabian Peninsula in 2012), and the novel coronavirus that emerged in December of 2019 in Wuhan,
China.4,7 In January of 2020, this new coronavirus was
named SARS-CoV-2 as the causative agent of the disease,
COVID-19. It is most closely related to SARS-CoV with a
genomic sequence identity of 79%.8,9 On March 11, 2020,
a COVID-19 global pandemic was declared by the
WHO.10 As of February 25, 2022, there are 5,911,081
confirmed deaths worldwide due to COVID-19 (https://
covid19.who.int/). The progression of the pandemic saw
variants of SARS-CoV-2 emerge, some with increased
virus transmission resulting in a global spread.11–15
Currently, the omicron variant (https://www.who.int/
en/activities/tracking-SARS-CoV-2-variants/) is responsible for the majority of the infections in the
United States (https://covid.cdc.gov/covid-data-tracker/
#variant-proportions). The omicron variant shows the
potential to be not only more infectious than the delta
variant with a higher chance of reinfection amongst
previously infected individuals, but can significantly
evade immunity achieved through current vaccinations.16–19 Recent emergence of the fast-spreading Omicron variant has reinvigorated efforts to develop more
effective countermeasures against COVID-19.18 Effective vaccines are available to fight the spread of the disease, but each new variant carries the possibility to
evade the immunity offered by existing vaccines.
Research into SARS-CoV-2 remains vital to curtail the
pandemic.
Coronaviruses are positive sense, single-strand RNA
viruses with four structural proteins: spike (S), envelope
(E), membrane (M), and nucleocapsid (N).8,20,21 The S
protein forms a homo-trimer with each protein composed
of two subunits named S1 (residues 14-685) and S2 (residues 686-1273).9,21,22 S1 is responsible for the initial binding to the aminopeptidase N segment of the angiotensinconverting enzyme (ACE2) receptor, whereupon it is
shed, and the S2 subunit mediates fusion with the target
cell membrane.21,23 This interaction between the S protein and the ACE2 receptor of the host's cells is required
for virus entry into the cell. Binding occurs with low
nanomolar affinity.9,21 The S protein is highly glycosylated, allowing it to evade the host organism's immune
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system by using glycosylation to mask up to 40% of the S
protein's surface area.22,24 Accounting for this potential
epitope shielding by glycosylation makes expressing S
protein in an expression system that will include such
glycosylation of spike protein far more useful for immunological assays.
It has recently been shown that transcription of ACE2
is regulated by bromodomain and extraterminal domain
(BET) proteins that bind acetylated residues on histones
to recruit transcriptional machinery.25,26 Inhibitors of
BET proteins have been shown to decrease ACE2 expression, spike protein binding, and SARS-CoV-2 infection in
lung epithelial cells and cardiomyocytes.27,28 Anti-ACE2
antibodies can similarly attenuate viral entry and infection through the occupation of ACE2 receptors, thus
blocking spike protein binding (i.e., ACE2 receptor blockade).25 The SARS-CoV-2 envelope protein is additionally
known to directly interact with BET proteins, but no
associated effects have been reported for viral infection.26
With the shift in focus of many laboratories toward
COVID-19 research, an efficient and reliable method for
purifying large amounts of glycosylated S protein is
needed. We chose to use baculovirus-based recombinant
spike protein expression in insect cells which provide Nglycosylation that mirrors mammalian cells, albeit with
simpler side chains with terminal mannose residues
instead of sialic acid residues.29 Insect cell expression systems offer significant advantages over mammalian cell
line expression systems. The proteins from insect cell
expression systems can have complex post-translational
modifications and show immunogenicity, antigenicity,
and biological activity similar to authentic natural proteins. Additional benefits include less expensive media,
ease of scalability, vectors that are safe for humans, and a
greatly reduced turn-around time from starting a culture
to expressing protein.30 In this paper, we demonstrate the
expression of four constructs of the original SARS-CoV-2
S protein ectodomain in insect cells using recombinant
baculovirus and purification of each using a simple and
robust method (Figure 1).21,23 The spike protein receptorbinding domain (RBD) enhanced green fluorescent protein (eGFP) fusion construct (S-RBD-eGFP) was designed
to be useful for biological studies. It is comprised of the
RBD portion of the S protein that includes the SD1
domain (319-591) with eGFP and 12x His tag bound by a
TEV cleavable linker domain on the C-terminus. The
linked eGFP makes the protein easy to track during purification and gives confidence that the construct is folded
correctly, as there is a strong relationship between the
correct folding of the C-terminal eGFP chromophore and
the absence of the upstream linked protein forming
inclusion bodies or aggregating.31,32 The S-Ecto-eGFP
construct is much the same, but with the full-length
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F I G U R E 1 Domain map of full-length spike protein and purified Spike constructs. (a) Full-length SARS-CoV-2 spike protein. CD,
connector domain; CH, central helix; CP, cytoplasmic peptide; FP, fusion peptide; HR1, heptad repeat 1; HR2, heptad repeat 2; NTD, Nterminal domain; RBD, receptor-binding domain; RBM, receptor-binding motif; SD1/2, subdomain 1 and 2; SS, signal sequence; TM,
transmembrane domain. (b) S-RBD-eGFP, (c) S-Ecto-eGFP, (d) S-Ecto-HexaPro(+F), and (e) S-Ecto-HexaPro(-F). Respective domains are
insect cell Secretion Peptide (yellow), spike protein (Blue), TEV cleavage site (grey), linker regions (magenta), foldon domain (orange), 12x
His Tag (peach)

spike ectodomain replacing the RBD. The S-EctoHexaPro(+F) construct is nearly identical to one previously expressed and tested with mammalian expiCHO
cells.33 This construct contains six proline mutations that
stabilize the protein, a C-terminal foldon domain to assist
with trimerization, and a TEV cleavable 12x His tag
attached by a flexible linker region.34,35 This construct
was included in this study to test if the proline mutations
will increase protein production in insect cells. The SEcto-HexaPro(-F) construct is the same as the S-EctoHexaPro(+F) construct, only with the foldon domain
removed. This was done to test if the foldon domain has
an impact on protein expression levels. All four of the
constructs tested had an insect cell secretion peptide
added to the N-terminus, and the three ectodomain constructs had the furin cleavage site eliminated (682-685 on
S-Ecto-eGFP) by mutation from RRAR to GSAS,
preventing S1/S2 subunit cleavage.4,35 Sequences for all
constructs are available in Figure S1.
Each of the purified constructs was tested for binding
activity using surface plasmon resonance (SPR), demonstrating that the proteins contain active and functionally
folded RBD by their ability to bind ACE2. In addition, we
show that the ACE2 receptor blockade or treatment with

BET inhibitors (e.g., JQ1 and RVX-208) significantly
reduced the binding between the spike protein and ACE2
in cultured human epithelial cells.

2 | RESULTS A ND DISCUSSION
2.1 | Purification of spike-ectodomain
The purification of S-Ecto-HexaPro(+F), S-Ecto-HexaPro
(-F), S-RBD-eGFP, and S-Ecto-eGFP sequences all follow
the same purification protocol. The affinity tag and
optional eGFP domain are attached to the S-Ecto and SRBD domains by a flexible linker that can be cleaved
with TEV protease. This cleavage method was chosen
because the remaining portion of the TEV protease cleavage sequence (ENLYQ) is not found in the human proteome, and so would not produce a self-recognition epitope
in humans. To ensure that the proteins are glycosylated,
have high levels of expression, and that the cell culturing
was as user-friendly as possible, we chose to express the
protein in insect cells using a baculovirus vector. Sf9 and
Tni cells were selected for this purpose as Sf9 cells are
one of the most widely used for insect cell cultures, while

STRUBLE ET AL.

4 of 11

Tni cells have been shown to express and secrete more
recombinant protein than other insect cell lines. The
MOI of 5 and incubation time of 3 days was chosen
because it resulted in the optimal amount of protein
when the media was tested by western blot (not shown).
We tested three types of immobilized metal affinity
chromatography (IMAC) resins: Ni-NTA Agarose
(Qiagen), Ni Sepharose excel (Cytiva), INDIGO-Ni agarose resin. We found that the cell media leached the
nickel ions from the Ni-NTA Agarose resin, significantly
reducing the final protein yield. Excel and INDIGO-Ni
are both chemical resistant resins, and both showed no
observable metal ion leaching. We decided to proceed
with our experiments using the INDIGO-Ni resin, as the
Excel resin co-purified more impurities (not shown).
We took note of the differences in total protein purified for each construct and each cell line tested (Table 1).
The protein yield from 1 L of cultured SF9 cells was 3.5,
0.16, 1.2, and 0.58 mg for S-RBD-eGFP, S-Ecto-eGFP, SEcto-HexaPro(+F), and S-Ecto-HexaPro(-F), respectively.
The yield from 1 L of cultured Tni cells was 0.2, 4.4, and
1 mg from S-Ecto-eGFP, S-Ecto-HexaPro(+F), and SEcto-HexaPro(-F), respectively. S-RBD-eGFP protein
yield for Tni cells was not performed. After removal of
the affinity tag (or affinity tag + eGFP), 5 μg of each protein was loaded onto SDS-PAGE and stained with
SimplyBlue SafeStain. We see all the proteins run at
higher molecular weight than what the expected protein
size, presumably due to the presence of glycosylation.
With the tags removed, S-RBD-eGFP has a calculated
MW of 31.6 kDa and runs on SDS-PAGE at 36 kDa, SEcto-eGFP has a calculated MW of 136.0 kDa and runs at
160 kDa, S-Ecto-HexaPro(+F) has a calculated MW of
137.9 kDa and runs at 170.0 kDa, and the S-EctoHexaPro
(-F) has a calculated MW of 134.6 kDa and runs at

TABLE 1

170.0 kDa. The affinity tag (or affinity tag + eGFP) was
cleaved from all constructs by TEV protease with varying
efficiencies. Using the same type of resin binds the Histagged TEV protease, cleaved His-tags, spike proteins
with intact His-tags, and the non-specifically bound proteins eluted during the first step of purification. This
results in extremely pure protein in the flow-through
(Figure 2). As tag removal would be required for certain
experiments, it is important to be able to cleave the affinity tag from all three subunits of the spike ectodomain as
an uncleaved tag on a single subunit will result in all
three subunits being removed by the final nickel affinity
column and the final protein yield will be reduced.
We tested two types of centrifugal concentrator membranes for their effectiveness in concentrating these proteins: polyethersulfone and regenerated cellulose. We
found that all three of the spike ectodomain proteins
would bind in a non-recoverable fashion to the polyethersulfone membranes while the S-RBD-eGFP behaved
normally. All the proteins tested behaved normally when
concentrated with a regenerated cellulose membrane
such as the Amicon Ultra 15 (Millipore).

2.1.1 | Deglycosylation of the SARS-CoV-2 SEcto-eGFP
Spike ectodomain normally has 22 N-glycosylation and
2 O-glycosylation sites (Figure 3).24,36,37 We explored the
type of glycosylation on the purified S-Ecto-eGFP by
treatment with N-glycanase (PNGase F), O-glycanase,
and Sialidase A. Treatment of S-Ecto-eGFP with N-

Protein yield data

Construct

Protein yield
from
Sf9 cells (mg)

Protein yield
from
Tni cells (mg)

S-RBD-eGFP (#186)

3.5

NA

S-Ecto-eGFP (#192)

0.16

0.2

S-Ecto-HexaPro(+F)
(#314)

1.2

4.4

S-Ecto-HexaPro(-F)
(#326)

1

Note: A comparison between yields of recombinant protein purified from 1 L
of cell media after purification with a single round of INDIGO Ni agarose
resin from both Sf9 cells and Tni cells, as well as the amount of pure protein
that could be purified after tag cleavage with TEV protease. The calculated
MW values are given alongside the observed MW values for the proteins
with tags cleaved. S-RBD-eGFP protein yield in Tni cells was not performed.

F I G U R E 2 SDS-PAGE of fully purified SARS-CoV-2 spike
ectodomains and RBD with Affinity tag and eGFP removed. Five
microgram of (a) S-Ecto-HexaPro(+F), (b) S-Ecto-HexaPro(-F),
(c) S-RBD, and (d) S-Ecto were resolved on 4–12% SDS-PAGE
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F I G U R E 3 Glycosylation of SARSCoV-2 S-ectodomain. (a) Schematic
representation of SARS-CoV-2 S
protein's N- and O-linked glycosylation
sites. (b) Immunoblotting analysis of
Sialidase A, O-glycanase, and Nglycanase treated S-ectodomain

glycanase (PNGase F) showed increased mobility shift
and destabilization of the protein due to the loss of heavy
N-glycans (Figure 3). However, the treatment of S-EctoeGFP with O-glycanase showed a slightly decreased protein mobility shift, which supports the previous findings
that S-protein has only two O-linked core-1 derived glycans in its RBD backbone (Figure 3). Conversely, treatment of S-Ecto-eGFP with Sialidase A (which removes
sialic acid group) either alone or in combination with
either N-glycanase or O-glycanase or together induced a
noticeable change in the migration of S-Ecto-eGFP. This
decreased mobility shift may be due to the loss of negatively charged sialic acid groups in the N- and O-linked
glycans (Figure 3). These results indicate that the SARSCoV-2 spike protein has both highly sialylated N- and Olinked glycans.

2.1.2 | Binding of the S ectodomain
constructs to the hACE2 receptor
The binding of the purified S ectodomains to hACE2 was
tested using SPR (Figure 4) to test their activity relative to
wild-type proteins made in human 293T cells. The interaction between hACE2 and wild type SARS-CoV-2 spike
trimers has a KD of 14.7 nM.9,21 The interaction between
hACE2 and S-Ecto-eGFP, S-Ecto-HexaPro(+F), and SEcto-HexaPro(-F) have KD values of 55.1, 72.5, and
20.3 nM, respectively. Although the affinity of these purified recombinant proteins to hACE2 is lower (higher
KD), they share the same order of magnitude as the wild
type SARS-CoV2 spike trimer indicating that they share a
high affinity for hACE2. The binding between wild-type
SARS-CoV2 RBD and hACE2 has a KD of 4.7 nM.9 The
binding between hACE2 and the S-RBD-eGFP construct
was 185 nM. This construct binds with only moderate
affinity compared to the wild-type SARS-CoV2 RBD. The

high-affinity binding of the spike ectodomain constructs
and the moderate affinity of the S-RBD-eGFP construct
demonstrates that the constructs are properly folded and
functionally active like native SARS-CoV-2 spike
proteins.

2.1.3 | Targeting ACE2 receptor inhibits
binding by the S-Ecto-eGFP
The functional binding of S-Ecto-eGFP to hACE2 on
bronchial epithelial Calu-3 cells was additionally evaluated via flow cytometry. Calu-3 cells incubated with
S-Ecto-eGFP demonstrated a 2.6-fold greater median
GFP fluorescence intensity (MFI) than cells incubated
with GFP-His tag control (Figures 5 and 6). Blocking the
hACE2 receptor with anti-ACE2 significantly inhibited
S-Ecto-eGFP binding compared to IgG control (Figure 5).
Two BET inhibitors were used in this study to downregulate hACE2 expression on Calu-3 cells.27 Both JQ1
and apabetalone (RVX-208) significantly inhibited SEcto-eGFP binding compared to vehicle control
(Figure 6). JQ1 is a pan-BET inhibitor with equal affinity
for the two BET bromodomains (BD1 and BD2), while
the clinically advanced RVX-208 preferentially targets the
BD2 bromodomain. RVX-208 has an established favorable safety profile in clinical trials for cardiovascular indications and is now the focus of a clinical trial for COVID19 treatment compared to standard of care (Clinical trial
identifier: NCT04894266).28,38,39 In addition to reducing
SARS-CoV-2 infection, RVX-208 may play a pivotal role
in controlling hyperinflammatory immune responses that
can cause long-term tissue damage in patients.26,28,38,40,41
BET inhibitors have also been reported to decrease the
expression of immune inhibitory receptors, such as PDL1 and LAG3 which hinder T-cell function.42 High
expression of LAG3 correlates with more severe disease
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F I G U R E 4 Activity assessment of purified S-Ecto and RBD constructs for binding to hACE2 protein in SPR. (a) SPR curve-fit plots of
spike ectodomain with six proline mutations, with and without a foldon domain ((S-Ecto-HexaPro(+F) and (S-Ecto-HexaPro(-F)
respectively), spike ectodomain with eGFP (S-Ecto-eGFP), and spike receptor-binding domain with eGFP (S-RBD-eGFP) at concentrations of
2, 10, and 50 μg/ml binding to hACE2. (b) KD values with standard deviation (SD) of each recombinant protein binding to hACE2

in COVID-19 patients, with normalization of receptor
levels witnessed during recovery.43

3 | C ON C L U S I ON
We demonstrated a robust and reliable method for purifying multiple constructs of the S ectodomain that is easy
to replicate and can be adapted to different variants of
the spike domain to obtain purified active proteins. For
all constructs tested, we found that the overall yield was
higher when Tni cells were used, with the S-EctoHexaPro(+F) specifically showing a large 3.7! increase
in yield. Compared to the similar construct expressed in
mammalian FreeStyle 293-F cells by Hsieh et al.,33 we
find that the mammalian cell system has a 2.3! increase
in yield over our method; however, the ease of culturing

insect cells over mammalian cells may prove appealing.
Our research also shows the importance of the six stabilizing proline mutations in insect cells, as the yield from
Tni cells of S-Ecto- HexaPro(-F) and S-Ecto-HexaPro(+F)
constructs showed a 5! and 22! increase, respectively
when compared to S-Ecto-eGFP. It is, however, possible
that the change in yield is due to the additional eGFP
being produced. These results closely match what was
seen by Hsieh et al.,33 where spike ectodomain with the
same HexaPro as our constructs was seen to have 10-fold
higher expression as a two proline mutant, and the two
proline mutant was developed to have higher and more
stable expression than the native spike ectodomain.21
When our results are compared to other published
methods for producing full-length spike ectodomain, we
find that Wrapp et al.21 using FreeStyle 293 cells had a
yield of 0.5 mg/L, while Hsieh et al.33 using ExpiCHO
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F I G U R E 5 Functional S-Ecto-eGFP binding is reduced by
ACE2 receptor blockade. Calu3 cells were incubated with 40 μg/ml
α-ACE2 or goat IgG antibody (IgG) for 45 min prior to incubation
with the S1-ectodomain-eGFP protein. Data are represented as the
fold increase of GFP MFI (median fluorescent intensity) compared
to GFP-His tag control (mean ± SEM). N = 4 independent
experiments. *p < .05

F I G U R E 6 Reduced functional S-Ecto-eGFP binding to surface
ACE2 in BET-inhibitor treated Calu3 cells. Calu3 cells were treated
with BET inhibitors (JQ1, RVX-208; RVX) or control DMSO vehicle
(VEH) for 24 hr prior to incubation with the S1-ectodomain-eGFP
protein. Data are represented as the fold increase of GFP MFI
(median fluorescent intensity) compared to GFP-His tag control
(mean ± SEM). N = 3–4 independent experiments.
*p < .05, **p < .001

cells had a yield of 32.5 mg/L. We find our yields closest
to Wrapp et al.,21 with lower yields using S-Ecto-eGFP
(0.16 mg/L from SF9 cells and 0.2 mg/L from Tni cells)
and higher yields with S-Ecto-HexPro(+F) (1.2 mg/L
with Sf9 cells and 4.4 mg/L with Tni cells) and S-EctoHexPro(-F) (0.58 mg/L with Sf9 cells and 1.0 mg/L with
Tni cells). The yield for all of our constructs was lower
than what was reported by Hsieh et al.33 When we compare our S-RBD-eGFP construct to our previously published RBD with maltose-binding protein tag (RBD-MBP)
expressed in Escherichia coli BL21(DE3) cells using
CyDisCO to form the required disulfide bonds, we find
that our method yields 3.5 mg/L using Sf9 cells opposed
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to the 0.5 mg/L using the E. coli system, and the S-RBDeGFP construct is likely glycosylated.44
As new SARS-nCoV-2 variants continue to emerge,
future studies adding to the body of research about the
novel coronavirus as well as the development of countermeasures against the COVID-19 disease itself will be
required. The process demonstrated provides an entry for
small laboratories to begin research into SARS-CoV-2 S
protein in vitro or in vivo studies, as well as a rapid startup for laboratories that are already working in the field.
We also demonstrated that the novel S-Ecto-eGFP
construct could be used to measure changes in functional
SARS-CoV-2 spike protein binding to commonly infected
cells, such as those of the lung epithelium. S1-Ecto-eGFP
binding, quantified by flow cytometry, is significantly
decreased by blocking the ACE2 receptor with ACE2
antibodies or by reducing ACE2 expression with BET
inhibitors. This is relevant because S-Ecto-eGFP functionality can be monitored through ACE2 receptor binding,
and we see a decrease in binding as a dose-dependent
response to these inhibitors.
Further, the S-Ecto-eGFP construct has already successfully been used in a published study concerning the
effect of bromelain on lessening the interaction between
the S-Ecto-eGFP and VeroE6 cells and the diminished
levels of SARS-CoV-2 infection in VeroE6 cells.45 In that
study, the S-Ecto-eGFP construct was used for multiple
experiments that included assessing ACE2 receptor binding, a serological assay where the S-Ecto-eGFP is recognized by COVID-19 positive patient samples, and
treatment with bromelain testing for susceptibility to
cleavage by the protease.

4 | METHODS
4.1 | Virus creation
The four spike protein sequences were ordered from
GenScript in pET28a vectors: S-Ecto-HexaPro(+F), SEcto-HexaPro(-F), S-RBD-eGFP, and the S-Ecto-eGFP
(S1). SF9 cells and BestBac 2.0 linearized Baculovirus
DNA were acquired from Expression Systems (catalog
number 91-200). Using the manufacturer's instructions
and the aforementioned plasmids, P0, P1, and (if needed)
P2 Baculovirus containing our sequence of interest were
created.

4.2 | Protein expression
SF9 (Spodoptera frugiperda) and Tni (Trichoplusia ni)
cells (Expression Systems) were grown in sterile PC flasks
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(Thermo Fisher Scientific) using ESF-921 media
(Expression Systems), in a shaking incubator with a 2 in.
orbit running at 160 RPM at 28" C. The day before infection, the cells were passaged to 1 ! 106 cells/ml into ESFAF media (Expression Systems). When the cells reached
2 ! 106 cells/ml the following day, they were infected
with the appropriate virus at an MOI of 5 and placed in a
separate shaking incubator using the same conditions,
whereupon they were left to shake for 72 hr. From this
point on, all steps were performed at room temperature
(RT) or higher to prevent misfolding of the protein.46
After 72 hr, one cOmplete ULTRA protease inhibitor tablet (Roche) was dissolved in each liter of media, and the
contents of the flasks were centrifuged at 400g for
10 min. The supernatant was decanted and centrifuged a
second time at 14,000g for 30 min. The supernatant was
then passed through a sterile filter and stored on the
benchtop at RT in sterile conditions.

protein was buffer exchanged into the wash buffer, and
the sample was incubated with the same amount of
INDIGO resin as used in the previous step, gently stirring
on the benchtop for 3 h. The mixture was then added to a
30-ml gravity-flow column (BIO-RAD), the column was
washed with 3 CV of wash buffer, and the flow-through
of this wash was collected. The cleaved 12x-His tags, HisTEV protease, and protein with uncleaved 12x-His tags
were eluted from the column with 3 CV of wash buffer
with added 500 mM imidazole. Amicon Ultra 15 (Millipore) with an MWCO of either 30 or 100 kDa were used
to concentrate samples. The cleaved and uncleaved samples were run on SDS-PAGE to monitor cleavage success.
The purity of the 12x-His tag cleaved fraction was confirmed by SDS-PAGE where 5 μg of the protein was
loaded onto the gel.

4.4.1 | Deglycosylation of the SARS-CoV-2 Sectodomain
4.3 | Protein purification
All purification steps are performed on the bench at
RT. INDIGO-Ni agarose resin (Cube Biotech) was rinsed
with wash buffer (20 mM Tris, pH 8.0, 1 M NaCl), added
to the media, and stirred at RT for 3 hr. After stirring, the
resin was allowed to settle for 30 min. The media was
then decanted and disposed of, and the resin suspended
in wash buffer. The suspended resin was added to 30-ml
gravity-flow columns (BIO-RAD) and washed with 10 CV
of wash buffer. The column was washed with 3 CV of
wash buffer containing 20, 40, 60, 80, and 100 mM imidazole were performed sequentially. The imidazole stock
solution (1 M) was adjusted to pH 8 with NaOH before
use. The protein was eluted with wash buffer containing
500 mM imidazole. Washes and elutions were concentrated using an AMICON Ultra-15100 kDa MWCO centrifugal concentrator (regenerated cellulose membrane,
Millipore Sigma) and run on ExpressPlus PAGE gels
(GenScript) and stained with SimplyBlue SafeStain
(Novex) to confirm the location of the eluted protein. Protein concentration was determined by A280 using calculated extinction coefficients based on the amino acid
sequence.

4.4 | 12x-His tag removal
Once the fraction with the correct molecular weight
(MW) band had been identified, it was incubated with
MHT237Δ TEV protease (1 mg of TEV protease for every
10 mg of target protein) either on the benchtop overnight
or for 2 hr at 37" C.47 Once cleavage was complete, the

Removal of N-glycans, O-glycans, and sialic acids from the
purified S-ectodomain was performed by using a
Deglycosylation kit (Agilent, Santa Clara, CA) as per the
manufacturer's instructions. Briefly, 1 μg of S-ectodomain
was used for N-glycanase, O-glycanase, and Sialidase A
(1 μl/reaction) treatment at 37" C for 3 hr. After treatment,
the protein-enzyme mixtures were mixed with 2x Laemmli
buffer and boiled at 100" C for 5 min. The mixtures were
resolved on 4–20% SDS-PAGE and blotted with PVDF
membrane. The membrane was immunoprobed with an
anti-spike protein antibody as described.45

4.4.2 |

SPR-based hACE2-binding assay

A sensor chip was captured with recombinant
hACE2-AviTag protein from 293T cells (Acro Biosystems,
Newark, DE) followed by injection of 300 μl of freshly
prepared serial dilutions of S-Ecto-HexaPro(+F), S-EctoHexaPro(-F), S-RBD-eGFP, and S-Ecto-eGFP made with
Tni cells (Expression Systems) and passed over it at a
flow rate of 50 μl/min (contact duration 180 s) for the
association, and disassociation was performed over a
600-s interval. A mock surface and buffer-only injections
were used to correct for background signal. Bio-Rad ProteOn Manager (version 3.1) was used for data processing.

4.5 | Chemical compounds
Apabetalone (RVX-208) was a kind gift from Resverlogix
Corp. (Edmonton, AB, Canada) and JQ1 was purchased
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from Cayman Chemicals. Both compounds were dissolved in dimethyl sulfoxide (DMSO).
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Prahlad for their technical assistance.

Calu-3 were seeded at #150,000 cells per well in 24-well
plates and allowed to adhere for 24 hr before treatment.
Cells were treated with BET inhibitors (5 μM JQ1 or 10–
20 μM RVX-208) or vehicle (DMSO) in complete growth
medium for 24 hr. For antibody blocking conditions, cells
were incubated with 40 μg/ml anti-ACE2 (R&D Systems
#AF933) or goat IgG isotype control (R&D AB108C) in
PBS/2% FBS for 45 min, rocking at RT. For staining, all
test samples were incubated with 50 μg/ml S-Ecto-eGFP
or control GFP-His tag protein (Sino Biological) and
Zombie NIR Fixable Viability dye (BioLegend) in PBS/2%
FBS for 30 min, rocking at RT. Samples were suspended
in PBS/2% FBS for flow cytometry analyses.
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4.8 | Flow cytometry
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4.6 | Cell culture
Human bronchial epithelial Calu-3 cells (a kind gift from
Dr. Dickinson, UNMC; originally from ATCC) were
maintained at 37" C in a humidified environment
enriched with 5% CO2 in Eagle's minimum essential
medium (EMEM, ATCC) supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml
streptomycin.

4.7 | Spike protein binding

S-Ecto-eGFP protein binding to live Calu3 cells was measured using a NovoCyte 2060R flow cytometer and analyzed with NovoExpress version 1.4.1 software (Agilent
Technologies).
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4.9 | Statistical analysis
Statistical significance was determined through student's
t tests using GraphPad Prism v9 software (San Diego, CA).
Comparisons were done versus isotype or vehicle control,
and p values of <.05 were considered statistically significant.
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